CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
GTx-024drug
Likely dose
GTx-024 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02658448
NCT02658448Phase 2Completed
CompareCT.gov

GTx-024 as a Treatment for Stress Urinary Incontinence in Women: A Proof of Concept Study

GTx·interventional·Posted Jan 18, 2016·Updated Feb 1, 2021

In Brief

A Phase 2 clinical trial evaluating GTx-024 for Stress Urinary Incontinence. Completed, enrolled 19 participants across 3 sites.

Detailed Summary

The purpose of this study is to determine whether GTx-024 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStress Urinary Incontinence
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 18, 2016
Enrollment StartJan 1, 2016
Primary CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 10.5 years ago

Interventions

GTx-024drug

GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg